Lunsumio 1 mg concentrate for solution for infusion – Summary of Product Characteristics (SmPC) for healthcare professionals

1 NAME OF THE MEDICINAL PRODUCT

Lunsumio 1 mg concentrate for solution for infusion

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Lunsumio 1 mg concentrate for solution for infusion

Each vial contains 1 mg of mosunetuzumab in 1 mL at a concentration of 1 mg/mL.

Mosunetuzumab is a full-length, humanised anti-CD20/CD3 immunoglobulin (Ig)G1 isotype that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

Excipient with known effect

Each 1 mg vial contains 0.6 mg of polysorbate 20.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Concentrate for solution for infusion.

Clear, colourless liquid, pH 5.8 and osmolality of 240-356 mOsm/kg.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.

4.2 Posology and method of administration

Lunsumio must only be administered under the supervision of a healthcare professional qualified in the use of anti-cancer therapies, in a setting with appropriate medical support to manage severe reactions such as cytokine release syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) (see below and section 4.4).

It is important to check the product labels to ensure that the correct formulation (intravenous or subcutaneous fixed dose) is being administered to the patient, as prescribed. Lunsumio intravenous formulation is not intended for subcutaneous administration and should be administered via intravenous infusion only.

Posology

Prophylaxis and premedication

Lunsumio should be administered to well-hydrated patients.

Table 1 provides details on recommended premedication for CRS and infusion related reactions.

Table 1 Premedication to be administered to patients prior to Lunsumio infusion

The recommended dose of Lunsumio for each 21 day-cycle is detailed in Table 2.

Table 2 Dose of Lunsumio for patients with relapsed or refractory follicular lymphoma

Duration of treatment

Lunsumio should be administered for 8 cycles, unless a patient experiences unacceptable toxicity or disease progression.

Delayed or missed dose

Table 3 Recommendations for restarting therapy with Lunsumio intravenous infusion after dose delay

60 mg

Cycle 1 Day 15

*For the Day 1, Day 8, and Day 15 doses in the next cycle, administer premedication as per Table 1 for all patients

Note that all references to Cycle and Day are to the nominal Cycle and Day.

Dose modification

Patients who experience grade 3 or 4 reactions (e.g. serious infection, tumour flare, tumour lysis syndrome) should have treatment temporarily withheld until symptoms are resolved (see section 4.4).

Cytokine Release Syndrome

CRS should be identified based on clinical presentation (see section 4.4). Patients should be evaluated and treated for, other causes of fever, hypoxia, and hypotension, such as infections/sepsis. Infusion related reactions (IRR) may be clinically indistinguishable from manifestations of CRS. If CRS or IRR is suspected, patients should be managed according to the recommendations in Table 3.

Table 4 CRS grading¹ and management

¹ ASTCT = American Society for Transplantation and Cellular Therapy. Premedication may mask fever, therefore if clinical presentation is consistent with CRS, please follow these management guidelines.

² If CRS is refractory to management, consider other causes including haemophagocytic lymphohistiocytosis

³ Dexamethasone should be administered at 10 mg intravenously every 6 hours (or equivalent) until clinical improvement

⁴ In study GO29781, tocilizumab was administered intravenously at a dose of 8 mg/kg (not to exceed 800 mg per infusion), as needed for CRS management ⁵ If no clinical improvement in the signs and symptoms of CRS occurs after the first dose, a second dose of intravenous tocilizumab 8 mg/kg may be administered at least 8 hours apart (maximum 2 doses per CRS event). Within each time period of 6 weeks of Lunsumio treatment, the total amount of tocilizumab doses should not exceed 3 doses

⁶ Low-flow oxygen is defined as oxygen delivered at < 6 L/minute. ⁷ Refer to Table 1 for additional information

⁸ High-flow oxygen is defined as oxygen delivered at ≥ 6 L/minute ⁹ Riegler L et al. (2019)

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) grading and management

ICANS should be identified based on clinical presentation (see Section 4.4). Rule out other causes of neurologic symptoms. If ICANS is suspected, it should be managed according to the recommendations in Table 5.

Table 5 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

on neuroimaging Treat with dexamethasone 10 mg intravenously every 6 hours, if not taking other corticosteroids, until improvement to Grade 1, then taper.

Alternatively, consider

administration of

methylprednisolone 1 000 mg per day intravenously for 3 days, if symptoms improve, then manage as above.

Consider non-sedating anti-seizure medication for seizure prophylaxis until resolution of ICANS. Use anti-seizure medication for seizure management as needed.

^a American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading criteria.

^b If patient is arousable and able to perform Immune Effector Cell-Associated Encephalopathy (ICE) Assessment, assess: Orientation (oriented to year, month, city, hospital = 4 points); Naming (name 3 objects, e.g., point to clock, pen, button = 3 points); Following Commands (e.g., “show me 2 fingers” or “close your eyes and stick out your tongue” = 1 point); Writing (ability to write a standard sentence = 1 point; and Attention (count backwards from 100 by ten = 1 point). If patient is unarousable and unable to perform ICE Assessment (Grade 4 ICANS) = 0 points. ^c Consider the type of neurologic toxicity before deciding to withhold Lunsumio. ^d See Delayed or missed dose for guidance on restarting Lunsumio after dose delay. ^e Evaluate benefit/risk before restarting Lunsumio.

Special populations

Elderly

No dose adjustment of Lunsumio is required in patients ≥ 65 years of age (see section 5.2).

Renal impairment

Lunsumio has not been studied in patients with severe renal impairment. Dose adjustments are not considered necessary in patients with mild to moderate renal impairment based on pharmacokinetics (see section 5.2).

Hepatic impairment

Lunsumio has not been studied in patients with hepatic impairment. Dose adjustments are not considered necessary based on pharmacokinetics (see section 5.2).

Paediatric population

The safety and efficacy of Lunsumio in children below 18 years of age have not yet been established.

Method of administration

Lunsumio is for intravenous use only.

Lunsumio must be diluted using aseptic technique under the supervision of a healthcare professional. It should be administered as an intravenous infusion through a dedicated infusion line. Do not use an in-line filter to administer Lunsumio. Drip chamber filters can be used to administer Lunsumio.

The first cycle of Lunsumio should be administered over a minimum of 4 hours as intravenous infusion. If the infusions are well-tolerated in cycle 1, the subsequent cycles may be administered over a 2-hours infusion.

Lunsumio must not be administered as intravenous push or bolus.

For instructions on dilution of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Traceability

In order to improve traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded.

Cytokine Release Syndrome (CRS)

CRS, including life-threatening reactions, have occurred in patients receiving Lunsumio (see section 4.8). Signs and symptoms included pyrexia, chills, hypotension, tachycardia, hypoxia, and headache. Infusion related reactions may be clinically indistinguishable from manifestations of CRS. CRS events occurred predominantly in cycle 1 and were mainly associated with Day 1 and Day 15 dose administrations.

Patients should be premedicated with corticosteroids, antipyretics and antihistamines at least through cycle 2. Patients must receive adequate hydration prior to the administration of Lunsumio. Patients should be monitored for signs or symptoms of CRS. Patients should be counselled to seek immediate medical attention should signs or symptoms of CRS occur at any time. Physicians should institute treatment with supportive care, tocilizumab and/or corticosteroids as indicated. (see section 4.2).

Serious infections

Serious infections such as pneumonia, bacteraemia, and sepsis or septic shock have occurred in patients receiving Lunsumio, some of which were life-threatening or fatal events (see section 4.8). Febrile neutropenia was observed in patients after receiving Lunsumio infusion.

Lunsumio should not be administered in the presence of active infections. Caution should be exercised when considering the use of Lunsumio in patients with a history of recurring or chronic infections (e.g., chronic, active Epstein-Barr Virus), with underlying conditions that may predispose to infections or who have had significant prior immunosuppressive treatment. Patients should be administered prophylactic antibacterial, antiviral and/or antifungal medicinal products, as appropriate. Patients should be monitored for signs and symptoms of infection, before and after Lunsumio administration, and treated appropriately. In the event of febrile neutropenia, patients should be evaluated for infection and managed with antibiotics, fluids and other supportive care, according to local guidelines.

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

ICANS have occurred in patients receiving Lunsumio, including serious and life threatening reactions. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Manifestations of ICANS reported in clinical trials included confusional state, lethargy, encephalopathy, depressed level of consciousness, and memory impairment. The majority of cases occurred during Cycle

1.

Patients should be monitored for signs and symptoms of ICANS following Lunsumio administration. Patients must be counselled to seek immediate medical attention should signs or symptoms occur at any time (see Patient card below).

Patients should be advised to exercise caution while (or avoid if symptomatic) driving, cycling or using heavy or potentially dangerous machines (see section 4.7).

At the first signs or symptoms of ICANS, manage according to the ICANS guidance provided in Table 4. Treatment with Lunsumio should be withheld or discontinued permanently as recommended.

Haemophagocytic lymphohistiocytosis

Haemophagocytic lymphohistiocytosis (HLH), including fatal cases, have been reported in patients receiving Lunsumio. HLH is a life-threatening syndrome characterized by fever, hepatomegaly and cytopenias. HLH should be considered when the presentation of CRS is atypical or prolonged. Patients should be monitored for clinical signs and symptoms of HLH (see Section 4.2). For suspected HLH, Lunsumio must be interrupted and treatment for HLH initiated.

Tumour flare

Tumour flare has been reported in patients treated with Lunsumio (see section 4.8). Manifestations included new or worsening pleural effusions, localised pain and swelling at the sites of lymphoma lesions and tumour inflammation. Consistent with the mechanism of action of Lunsumio, tumour flare is likely due to the influx of T-cells into tumour sites following Lunsumio administration.

There are no specific risk factors for tumour flare that have been identified, however, there is a heightened risk of compromise and morbidity due to mass effect secondary to tumour flare in patients with bulky tumours located in close proximity to airways and/or a vital organ. Patients treated with Lunsumio should be monitored and evaluated for tumour flare at critical anatomical sites.

Tumour lysis syndrome (TLS)

TLS has been reported in patients receiving Lunsumio (see section 4.8). Patients must have adequate hydration prior to the administration of Lunsumio. Patients should be administered prophylactic anti-hyperuricemic therapy (e.g allopurinol, rasburicase), as appropriate. Patients should be monitored for signs or symptoms of TLS, especially patients with high tumour burden or rapidly proliferative tumours, and patients with reduced renal function. Patients should be monitored for blood chemistries and abnormalities should be managed promptly.

Immunisation

Live and/or live-attenuated vaccines should not be given concurrently with Lunsumio. Studies have not been conducted in patients who recently received live vaccines.

Patient card

The prescriber must discuss the risks of Lunsumio therapy with the patient. The patient should be provided with the patient card and instructed to carry it at all times. The patient card describes the common signs and symptoms of CRS and ICANS, including instructions on when a patient should seek medical attention.

Excipient with known effect

This medicinal product contains polysorbate 20. Each vial of Lunsumio 1 mg concentrate for solution for infusion contains 0.6 mg of polysorbate 20, and each vial of Lunsumio 30 mg concentrate for solution for infusion contains 18 mg of polysorbate 20, which is equivalent to 0.6 mg/mL

Polysorbates may cause allergic reactions.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

A transient clinically relevant effect on CYP450 substrates with a narrow therapeutic index (e.g. warfarin, voriconazole, cyclosporine, etc) cannot be excluded, since initiation of Lunsumio treatment causes a transient increase in cytokine levels which may cause inhibition of CYP450 enzymes. On initiation of Lunsumio therapy in patients being treated with CYP450 substrates with a narrow therapeutic index, therapeutic monitoring should be considered. The dose of the concomitant medicinal product should be adjusted as needed.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/Contraception

Women of childbearing potential should use effective contraception while receiving Lunsumio and for at least 3 months after the last infusion of Lunsumio.

Pregnancy

There are no data from the use of Lunsumio in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). Lunsumio is not recommended during pregnancy and in women of childbearing potential not using contraception.

Breast-feeding

It is unknown whether mosunetuzumab/metabolites are excreted in human milk. A risk to newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with Lunsumio therapy.

Fertility

No human data on fertility are available. No impairments were observed in male or female reproductive organs in the 26-week toxicity studies with cynomolgus monkeys at exposures (AUC) similar to exposure (AUC) in patients receiving the recommended dose.

4.7 Effects on ability to drive and use machines

Lunsumio has major influence on the ability to drive and use machines. Due to the potential for ICANS, patients receiving Lunsumio are at risk of depressed level of consciousness (see section 4.4). Due to the potential for ICANS, patients should be advised to exercise caution while (or avoid if symptomatic) driving, cycling or using heavy or potentially dangerous machines.

4.8 Undesirable effects

Summary of safety profile

The adverse reactions described in this section were identified from the pivotal clinical trial GO29781 in patients treated at the recommended intravenous dose (n=218) and the recommended subcutaneous dose (n=139). Patients had follicular lymphoma (51.8%), diffuse large B-cell lymphoma (26.9%), transformed follicular lymphoma (9.8%), mantle cell lymphoma (7.3%), Richter’s transformation (3.9%), and other histologies (0.3%). The median number of cycles of Lunsumio intravenously received was 8 (range 1 -17), 37% of patients received 8 cycles, and 15% received more than 8 cycles up to 17 cycles.

Patients received the recommended intravenous dose (n=218) and subcutaneous (n=139) dose are pooled (n=357) for this safety population. In this pooled safety population, the most common adverse reactions (≥ 20%) observed were cytokine release syndrome, neutropenia, rash and upper respiratory tract infection. The most common serious adverse reactions (≥ 2%) observed included cytokine release syndrome (CRS) (17% by ASTCT grading system), pyrexia (3%), sepsis (3%), upper respiratory tract infection (3%), and pneumonia (5%). Permanent discontinuation of Lunsumio due to an adverse reaction occurred in 5.8% (21/357) of patients. In patients who received the recommended intravenous dose (n=218).. CRS was the only adverse reaction that led to discontinuation in more than one patient (2 patients [0.9%]).

Tabulated list of adverse reactions

The adverse reactions are listed below by MedDRA system organ class (SOC) and categories of frequency. Frequency categories are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 6 Adverse reactions occurring in patients treated with Lunsumio

1 Upper respiratory tract infection includes upper respiratory tract infection, viral upper respiratory tract infection, nasopharyngitis, sinusitis, rhinovirus infection, sinusitis bacterial, viral sinusitis, respiratory tract infection, COVID-

19 and respiratory tract infection viral

2 Urinary tract infection (UTI) includes UTI, Escherichia UTI, pyelonephritis acute

3 Pneumonia includes pneumonia and COVID-19 pneumonia

4 Lower respiratory tract infection includes lower respiratory tract infection and bronchitis

5 Sepsis includes sepsis, septic shock, bacteraemia, Candida sepsis

6 Tumour flare includes tumour flare, pleural effusion, tumour inflammation and flank pain

7 Neutropenia includes neutropenia and neutrophil count decreased

8 Thrombocytopenia includes thrombocytopenia and platelet count decreased

9 Haemophagocytic lymphohistocytosis (HLH) includes HLH

10 By American Society for Transplantation and Cellular Therapy

11 Hypophosphatemia includes hypophosphatemia and blood phosphorus decreased

12 Hypokalemia includes hypokalemia and blood potassium decreased

13 Hypomagnesemia includes hypomagnesemia and blood magnesium decrease

14 Headache includes headache, migraine and head discomfort

15 Dizziness includes dizziness and vertigo

16 Consistent with the medical concept of ICANS according to American Society for Transplantation and Cellular

Therapy and includes confusional state, ICANS, lethargy, encephalopathy, depressed level of consciousness, and memory impairment

17 The frequency calculation is based on additional clinical studies

18 Rash includes rash, rash erythematous, exfoliative rash, rash macular, rash maculo-papular, rash pruritic, rash pustular, erythema, palmar erythema, dermatitis, dermatitis acneiform, dermatitis contact, palmar-planta erythrodysaesthesia and rash morbiliform

19 Grade 5 AEs only occurred for ADR terms HLH, pneumonia, sepsis and URTI (i.e., COVID-19) in mosunetuzumab subcutaneous injection (1 each) and for ADR terms Pneumonia and Sepsis in mosunetuzumab intravenous infusion (1 each)

Description of selected adverse reactions

Cytokine release syndrome (CRS)

In patients treated with Lunsumio intravenous infusion, CRS (ASTCT grading system) of any grade occurred in 39% (86/218) of patients, with grade 2 occurring in 14%, grade 3 occurring in 2.3%, and grade 4 occurring in 0.5% of patients treated with Lunsumio. The one patient with the grade 4 event was a patient with FL in the leukemic phase who also experienced concurrent TLS.

CRS of any grade occurred in 15% of patients after the Cycle 1, Day 1 dose; 5% after the Cycle 1, Day 8 dose; 33% after the Cycle 1, Day 15 dose, 5% occurred in patients after the Cycle 2 and 1% in Cycles 3 and beyond. The median time to CRS onset from the start of administration in Cycle 1 Day 1 was 5 hours (range: 1-73 hours), Cycle 1 Day 8 was 28 hours (range: 5-81 hours), Cycle 1 Day 15 was 25 hours (range: 0.1-391 hours), and Cycle 2 Day 1 was 46 hours (range: 12-82 hours). CRS resolved in all patients, and the median duration of CRS events was 3 days (range 1-29 days).

Of the 86 patients that experienced CRS, the most common signs and symptoms of CRS included pyrexia (98%), chills (36%), hypotension (35%), tachycardia (24%), hypoxia (22%) and headache (16%).

Tocilizumab and/or corticosteroids were used to manage a CRS event in 16% of patients: 6% received tocilizumab alone, 6% received corticosteroids alone, and 4% received both tocilizumab and corticosteroids. Among the 10% of patients who received tocilizumab (with or without a corticosteroid), 86% received only one dose of tocilizumab, with no more than two doses of tocilizumab administered for a single CRS event. In patients experiencing Grade 2 CRS, 48% of patients were treated with symptomatic management without corticosteroids or tocilizumab, 18% received tocilizumab alone, 21% received corticosteroids alone, and 12% received both corticosteroids and tocilizumab. Patients with grade 3 or grade 4 CRS received tocilizumab, corticosteroids, vasopressors and/or oxygen supplementation. Three percent of patients experienced hypotension and/or hypoxia without fever following Lunsumio administration; 2% of patients received tocilizumab and/or corticosteroids in the absence of fever.

Hospitalisations due to CRS occurred in 21% of patients and the median duration of hospitalisation was 5 days (range 0-30 days).

Neutropenia

In patients treated with Lunsumio intravenous infusion of subcutaneous injection, neutropenia of any grade occurred in 26.1% (93/357) of patients, including 22.7% Grade 3-4 events. The median time to onset of first neutropenia/neutrophil count decreased events was 50 days (range: 1-280 days), with median duration of 8 days (range: 1- 487 days). Of the 93 patients who had neutropenia/neutrophil count decreased events 68% (63/93) received treatment G-CSF to treat the events.

Serious infections

In patients treated with Lunsumio intravenous infusion of subcutaneous injection, serious infections of any grade occurred in 17% (60/257) of patients. Five (4%) of patients experienced serious infections concurrently with grade 3-4 neutropenia. The median time to onset of first serious infection was 92 days (range: 1-408 days), with median duration of 15.5 days (range: 2-174 days). Grade 5 events occurred in 2.5% (9/357) of patients, which included COVID-19, pneumonia, septic shock, and sepsis.

Immune Effector Cell-Associated Neurotoxicity Syndrome

Across a broader clinical trial population, Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurred in 2.1% (20/949) of patients, 19 patients had Grade 1-2 events and 1 patient had Grade 3 event. The majority of events occurred during the first cycle of treatment. The majority of cases resolved. The median time to onset from initial dose was 17 days (range: 1 to 48 days). The median duration was 3 days (range: 1-20 days). Immune Effector Cell-Associated Encephalopathy (ICE) scoring was not systematically performed across the reference trial populations.

Tumour flare

In patients treated with Lunsumio intravenous infusion or subcutaneous injection, tumour flare (including pleural effusion and tumour inflammation) occurred in 3.1% (11/357) of patients, which included 1.4% grade 2 and 1.4% grade 3 events. The median time to onset was 13 days (range 2-84 days), and median duration was 36 days (range 15-105 days).

Tumour Lysis Syndrome (TLS)

In patients treated with Lunsumio intravenous infusion or subcutaneous injection, TLS occurred in 0.6% (2/357) of patients, concurrent with CRS. One patient with follicular lymphoma was in the leukemic phase who experienced Grade 4 TLS. TLS onset was on days 2 and 24, and resolved within 3 and 6 days, respectively.

Reporting of suspected adverse reactions

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

4.9 Overdose

In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents; Other monoclonal antibodies and antibody drug conjugates, ATC code: L01FX25

Mechanism of action

Mosunetuzumab is an anti-CD20/CD3 T-cell engaging bispecific antibody targeting CD20-expressing B-cells. It is a conditional agonist; targeted B-cell killing is observed only upon simultaneous binding to CD20 on B-cells and CD3 on T-cells. Engagement of both arms of mosunetuzumab results in the formation of an immunologic synapse between a target B cell and a cytotoxic T cell leading to T-cell activation. Subsequent directed release of perforin and granzymes from T-cell activation through the immunologic synapsis induce B-cell lysis leading to cell death.

Lunsumio caused B-cell depletion (defined as CD19 B-cell counts < 5 cells/uL) after the initial cycle of administration (by Cycle 2 Day 1) by both intravenous and subcutaneous administration routes in a majority of patients (95.2% and 94.1% respectively) and depletion was maintained throughout the duration of treatment. Evidence of B-cell recovery was observed after fixed-duration treatment was completed.

Clinical efficacy and safety

Relapsed or refractory B-cell Non-Hodgkin's lymphoma

An open-label, multicentre, multi-cohort study (GO29781) was conducted to evaluate Lunsumio in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma for whom there was no available therapy expected to improve survival. In the follicular lymphoma (FL) cohort (n=90), patients with relapsed or refractory FL (Grade 1-3A) were required to have received at least two prior systemic therapies, including an anti-CD20 monoclonal antibody and an alkylating agent. Patients with FL Grade 3b and patients with transformed FL at study entry were not eligible; those with a history of transformed FL but FL Grade 1-3A at study entry were included in the FL cohort.

The study excluded patients with Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2, significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina), significant active pulmonary disease, impaired renal functions (Creatinine clearance [CrCl] < 60 mL/min with elevated serum creatinine level), active autoimmune disease requiring immunosuppressive therapy, active infections (i.e., chronic active EBV, acute or chronic hepatitis C, hepatitis B, HIV), progressive multifocal leukoencephalopathy, current or a history of CNS lymphoma or CNS disease, a history of macrophage activation syndrome / haemophagocytic lymphohistiocytosis, prior allogeneic stem cell transplant, or prior organ transplantation.

Patients received Lunsumio intravenously in a 21-day Cycle as follows:

• Cycle 1 Day 1: 1 mg
• Cycle 1 Day 8: 2 mg
• Cycle 1 Day 15: 60 mg
• Cycle 2 Day 1: 60 mg
• Cycle 3 and beyond Day 1: 30 mg

The median number of cycles was 8, 59% received 8 cycles, and 18% received more than 8 cycles up to 17 cycles.

The median age was 60 years (range 29 to 90 years) with 31% being > age 65, and 7.8% being ≥ age 75. Sixty-one percent were male, 82% were white, 9% were Asian, 4% were Black, 100% had an ECOG performance status of 0 or 1 and 34% of patients had bulky disease (at least one lesion > 6 cm). The median number of prior therapies was 3 (range: 2-10), with 38% receiving 2 prior therapies, 31% receiving 3 prior therapies and 31% receiving more than 3 prior therapies.

All patients received prior anti-CD20 and alkylator therapies, 21% received autologous stem cell transplant, 19% received PI3K inhibitors, 9% received prior rituximab plus lenalidomide therapy, and 3% received CAR-T therapies. Seventy-nine percent of patients were refractory to prior anti-CD20 monoclonal antibody therapy and 53% were refractory to both anti-CD20 monoclonal antibody and alkylator therapy. Sixty-nine percent of patients were refractory to the last prior therapy and 52% had progression of disease within 24 months of first systemic therapy.

The primary efficacy endpoint was complete response (CR) as assessed by an independent review facility (IRF) according to standard criteria for NHL (Cheson 2007). The efficacy results are summarised in Table 7.

Table 7 Summary of efficacy in patients with relapsed/refractory FL

CI=confidence interval; K-M=Kaplan-Meier; NR=not reached.

Clinical Cut-off: 27 August 2021

Hypothesis testing was conducted on the primary endpoint of IRF assessed CR rate. ¹ DOR is defined as the time from the initial occurrence of a documented PR or CR until the patient experiences an event (documented disease progression or death due to any cause, whichever occurs first).

² DOCR is defined as the time from the initial occurrence of a documented CR until the patient experiences an event (documented disease progression or death due to any cause, whichever occurs first).

The median follow-up for DOR was 14.9 months. Additional exploratory efficacy outcomes included the median time to first response (1.4 months, range: 1.1 - 8.9) and the median time to first complete response (3.0 months, range: 1.1- 18.9).

Immunogenicity

The immunogenicity of mosunetuzumab was evaluated using an enzyme-linked immunosorbent assay (ELISA). No patients tested positive for anti-mosunetuzumab antibodies in 418 ADA-evaluable patients who received Lunsumio single-agent intravenous treatments in Study GO27981. Based on the available information, the clinical relevance of anti-mosunetuzumab antibodies could not be assessed.

Paediatric population

The Licensing Authority has deferred the obligation to submit results of studies with Lunsumio in one or more subsets of the paediatric population in treatment of mature B-cell neoplasms (see section 4.2 for information on paediatric use).

Conditional approval

This medicinal product has been authorised under a so-called ‘conditional approval’ scheme. This means that further evidence on this medicinal product is awaited. The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.

5.2 Pharmacokinetic properties

Mosunetuzumab pharmacokinetic (PK) exposure increased in an approximately dose-proportional manner over the dose range studied, from 0.05 to 60 mg. The population pharmacokinetic following intravenous administrations of Lunsumio was described by a 2-compartment PK model with time-dependent clearance, which was parameterised as descending to a steady-state plateau (CLss) from a baseline value (CLbase) at the start of treatment according to transitional half-life of 16.3 days. Moderate to high pharmacokinetic variability for mosunetuzumab was observed and characterised by inter-individual variability (IIV) ranging from 18% to 86% coefficient of variation (CV) for mosunetuzumab PK parameters: IIV was estimated for CLbase (63% CV), central volume of distribution (31% CV), peripheral volume of distribution (25% CV), CLss (18% CV), and transitional half-life (86% CV).

After the first two Cycles (i.e., 42 days) of the dosing with Lunsumio, the serum concentration reaches the Cmax at the end of dose of Cycle 2 Day 1 of the Lunsumio intravenous infusion with an average maximal concentration of 17.9 µg/mL and %CV of 49.6%. The average total two cycles (42 days) mosunetuzumab exposure AUC was 126 day•mg/mL with %CV of 44.4%.

Absorption

Lunsumio is administered intravenously.

Distribution

The population estimate of central volume of distribution for mosunetuzumab was 5.49 L with intravenous infusion of Lunsumio. Because mosunetuzumab is an antibody, protein binding studies were not conducted.

Biotransformation

The metabolic pathway of mosunetuzumab has not been directly studied. Like other protein therapeutics, mosunetuzumab is expected to be degraded into small peptides and amino acids via catabolic pathways.

Elimination

Based on a population pharmacokinetic analysis, the estimated mean CLss and baseline clearance (CLbase) were 1.08 L/day and 0.584 L/day, respectively. The terminal half-life estimate was 16.1 days at steady state based on population pharmacokinetic model estimates. The results obtained in study GO29781 indicate that mosunetuzumab serum concentration reaches the Cmax at the end of the intravenous infusion and declines in a bi-exponential fashion.

Special populations

Elderly

Age did not have an effect on the pharmacokinetics of mosunetuzumab based on a population pharmacokinetic analysis with patients aged 19-96 years (n=439). No clinically important difference was observed in the pharmacokinetics of mosunetuzumab for patients in this age group.

Bodyweight

Like other therapeutic proteins, bodyweight was positively associated with mosunetuzumab estimated clearance and volume of distribution. However, based on exposure-response analysis and clinical exposure margins, considering the exposures in patients at either “low” (<50 kg) or “high” (≥112 kg) weight, no dose adjustment is required due to patient bodyweight.

Gender

Based upon population pharmacokinetic analysis, steady-state clearance of mosunetuzumab is marginally lower in females (~13%) compared to males. No dose adjustment is required due to gender, based on exposure-response analysis.

Race

Race (Asian vs. non-Asian) was not identified as a covariate influencing mosunetuzumab pharmacokinetics.

Renal impairment

No dedicated studies have been conducted to determine the effect of renal impairment on the pharmacokinetics of mosunetuzumab. The renal elimination of intact mosunetuzumab, an IgG monoclonal antibody, is expected to be low and of minor importance.

The population PK analysis of mosunetuzumab showed that creatinine clearance (CrCl) does not affect pharmacokinetics of mosunetuzumab. Pharmacokinetics of mosunetuzumab in patients with mild (CrCl 60 to 89 mL/min, n=178) or moderate (CrCl 30 to 59 mL/min, n=53) renal impairment were similar to those in patients with normal renal function (CrCl ≥ 90 mL/min, n=200). Pharmacokinetic data in patients with severe renal impairment (CrCl 15 to 29 mL/min) is limited (n=1), therefore no dose recommendations can be made. Lunsumio was not studied in patients with end-stage renal disease and/or who are on dialysis.

Hepatic impairment

No specific studies have been conducted to determine the effect of hepatic impairment on the pharmacokinetics of mosunetuzumab. IgGs are mainly eliminated via intracellular catabolism and hepatic impairment is not expected to influence clearance of mosunetuzumab.

The population PK analysis of mosunetuzumab showed that hepatic impairment does not affect pharmacokinetics of mosunetuzumab. Pharmacokinetics of mosunetuzumab in patients with mild hepatic impairment (total bilirubin > ULN to 1.5 x ULN or AST > ULN, n=53) were similar to those in patients with normal hepatic function (n=384). The number of patients with moderate hepatic impairment is limited (total bilirubin > 1.5–3 x ULN, any AST, n=2) and no patients with severe hepatic impairment have been studied.

Paediatric population

No studies have been conducted to investigate the pharmacokinetics of mosunetuzumab in the paediatric population (< 18 years old).

5.3 Preclinical safety data

Systemic toxicity

Key nonclinical findings with mosunetuzumab identified in single- and repeat-dose toxicity studies up to 26-weeks in duration included transient post-dose CRS primarily limited to the first dose, vascular/perivascular inflammatory cell infiltrates that were primarily in the CNS and infrequently in other organs that were likely secondary to cytokine release and immune cell activation, and increased susceptibility to infection following chronic dosing due to sustained B-cell depletion.

All of the findings were considered pharmacologically-mediated effects and reversible. Across studies there was a single incidence of convulsion in one animal at Cmax and AUC exposures (time-averaged over 7 days) of 3.3- and 1.8- fold higher, respectively, than those in patients receiving Lunsumio at the recommended dose and schedule in Study GO29781.

Impairment of fertility

An assessment of the male and female reproductive organs was included in a 26-week chronic toxicity study in sexually mature cynomolgus monkeys administered by intravenous infusion. Mosunetuzumab had no effect on either male or female reproductive organs at exposures (AUC) similar to exposure (AUC) in patients receiving the recommended dose.

Reproductive toxicity

No developmental toxicity studies in animals have been conducted with mosunetuzumab. Based on low placental transfer of antibodies during the first trimester, the mechanism of action and available data of mosunetuzumab, and the data on the anti-CD20 antibody class, the risk for teratogenicity is low. Studies with mosunetuzumab in non-pregnant animals have demonstrated that prolonged B-cell depletion can lead to increased risk of opportunistic infection, which may cause foetal loss. Transient CRS associated with Lunsumio administration may also be harmful to pregnancy.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

L-histidine

L-methionine

Acetic acid (pH adjustment)

Sucrose

Polysorbate 20 (E 432)

Water for injections

6.2 Incompatibilities

• Do not mix Lunsumio with, or administer through the same infusion line, as other medicinal products.
• Do not use solvents other than sodium chloride 9 mg/mL (0.9%) solution for injection or sodium chloride 4.5 mg/mL (0.45%) solution for injection to dilute Lunsumio since its use has not been tested.
• No incompatibilities have been observed between Lunsumio and intravenous infusion bags with product contacting materials of polyvinyl chloride (PVC), or polyolefins (PO) such as polyethylene (PE) and polypropylene (PP). In addition, no incompatibilities have been observed with infusion sets or infusion aids with product contacting materials of PVC, PE, polyurethane (PUR), polybutadiene (PBD), silicone, acrylonitrile butadiene styrene (ABS), polycarbonate (PC), polyetherurethane (PEU), fluorinated ethylene propylene (FEP), or polytetrafluorethylene (PTFE), or with drip chamber filter membrane composed of polyamide (PA).
• Do not use an in-line filter.

6.3 Shelf life

Unopened vial

3 years

Diluted solution

Chemical and physical in-use stability has been demonstrated for 24 hours at 2 °C - 8 °C and 24 hours at 9 °C - 30 °C.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

6.4 Special precautions for storage

Store in a refrigerator (2 °C - 8 °C).

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

For storage conditions after dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

1 mg concentrate for solution for infusion

Type I glass-vial with a fluororesin-laminated rubber stopper and an aluminium seal with a plastic dark grey flip-off

cap containing 1 mg of concentrate for solution for infusion.

Pack of one vial.

6.6 Special precautions for disposal

General precautions

To prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is Lunsumio for intravenous infusion and not Lunsumio for subcutaneous injection.

Lunsumio contains no preservative and is intended for single-dose only. Proper aseptic technique throughout the handling of this medicinal product should be followed. Do not shake.

Instructions for dilution

Lunsumio must be diluted into a PVC or polyolefin (PO) such as polyethylene (PE) and polypropylene infusion bag containing sodium chloride 9 mg/mL (0.9%) solution for injection or sodium chloride 4.5 mg/mL (0.45%) solution for injection by a healthcare professional using aseptic technique prior to administration.

Use sterile needle and syringe to prepare Lunsumio. Discard any unused portion.

A dedicated infusion line should be used during intravenous administration.

Do not use an in-line filter to administer Lunsumio.

Drip chamber filters can be used to administer Lunsumio.

Preparation for infusion

1. 1. Withdraw and discard a volume of sodium chloride 9 mg/mL (0.9%) solution for injection or sodium chloride 4.5 mg/mL (0.45%) solution for injection equal to the volume of the Lunsumio required for the patient’s dose from the infusion bag according to the Table 8 below.
2. 2. Withdraw the required volume of Lunsumio from the vial using a sterile syringe and dilute into the infusion bag. Discard any unused portion left in the vial.

Table 8: Dilution of Lunsumio

1. 3. Gently mix the infusion bag by slowly inverting the bag. Do not shake.
2. 4. Inspect the infusion bag for particulates and discard if present.
3. 5. Apply the peel-off label from the leaflet to the infusion bag.

For storage conditions of the infusion bags, see section 6.3.

Disposal

The release of pharmaceuticals into the environment should be minimised. Medicinal products should not be disposed of via wastewater and disposal through household waste should be avoided.

The following points should be strictly adhered to regarding the use and disposal of syringes and other medicinal sharps:

• Needles and syringes should never be reused.
• Place all used needles and syringes into a sharps container (puncture-proof disposable container).

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Roche Products Limited

6 Falcon Way, Shire Park

Welwyn Garden City

AL7 1TW

United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PLGB 00031/0933

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

02/06/2026

10 DATE OF REVISION OF THE TEXT

01/10/2026